Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The $1.95 billion Operation Warp Speed contract excludes government rights to inventions or production know-how developed in the manufacture of the COVID-19 vaccine. -
Newly released COVID-19 vaccine contracts include weakened protections against potential price gouging. Several key federal contracts still haven't been disclosed by the government. -
Drug industry veteran Moncef Slaoui is a key figure in Operation Warp Speed's push to develop COVID-19 coronavirus vaccines. His employment terms raised concerns about potential conflicts of interest. -
Most of the federal contracts with companies involved in the crash program to make COVID-19 vaccines haven't been made public. The lack of disclosure raises questions about accountability. -
A milestone in the development of COVID-19 vaccines will take place Thursday when the Food and Drug Administration will ask a panel of experts for advice on how to evaluate the vaccines.
-
Members of Congress and advocacy groups say Operation Warp Speed should release its contracts with vaccine makers after NPR reporting found the terms of many aren't public. -
More than $6 billion in federal funding has been routed through a firm that manages defense contracts, making the agreements subject to less federal scrutiny and transparency. -
Health policy researchers say Trump may not be able to pay for the cards, which fall short of lasting policy changes to curb high drug prices. -
The Centers for Disease Control and Prevention released plans for the distribution of coronavirus vaccines. The logistical challenges could be as daunting as the scientific ones.
-
The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?
